J Liver Cancer.  2022 Sep;22(2):93-102. 10.17998/jlc.2022.03.28.

Combination of interventional oncology local therapies and immunotherapy for the treatment of hepatocellular carcinoma

• Kim DH

• KMID: 2534236
• DOI: http://doi.org/10.17998/jlc.2022.03.28

Abstract

Interventional oncology (IO) local therapies of hepatocellular carcinoma (HCC) can activate anti-cancer immunity and it is potentially leading to an anti-cancer immunity throughout the body. For the development of an effective HCC treatment regime, great emphasis has been dedicated to different IO local therapy mediated immune modulation and possible combinations with immune checkpoint inhibitor immunotherapy. In this review paper, we summarize the status of combination of IO local therapy and immunotherapy, as well as the prospective role of therapeutic carriers and locally administered immunotherapy in advanced HCC.

Keyword

Hepatocellular carcinoma; Interventional radiology; Immunotherapy; Nanomedicine

Figure

• 

  Figure 1. Combination of IO local therapy and ICI immunotherapy of HCC. Combination of IO local therapies and locally delivered ICI immunotherapy enhances local immunogenicity, releasing tumor antigen and inducing immunogenic cell death. Modulated immunity in HCC effectively unleash the suppressed anti-cancer immune responses with circulating educated CTLs. IO, interventional oncology; ICI, immune checkpoint inhibitor; HCC, hepatocellular carcinoma; CTL, cytotoxic lymphocyte; APC, antigen presenting cell; IL-2, interleukin-2; TRAE, treatment related-adverse effect.

Reference

1. Chow PK, Tai BC, Tan CK, Machin D, Win KM, Johnson PJ, et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology. 2002; 36:1221–1226.

2. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988; 62:479–483.

3. Ahmed M, Goldberg SN. Thermal ablation therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2002; 13:S231–S244.

4. Clark TW, Soulen MC. Chemical ablation of hepatocellular carcinoma. J Vasc Interv Radiol. 2002; 13:S245–S252.

5. Vitale A, Peck-Radosavljevic M, Giannini EG, Vibert E, Sieghart W, Van Poucke S, et al. Personalized treatment of patients with very early hepatocellular carcinoma. J Hepatol. 2017; 66:412–423.

6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236.

7. N'Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009; 50:1475–1483.

8. Ackerman NB. Experimental studies on the circulation dynamics of intrahepatic tumor blood supply. Cancer. 1972; 29:435–439.

9. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007; 30:6–25.

10. Biolato M, Marrone G, Racco S, Di Stasi C, Miele L, Gasbarrini G, et al. Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci. 2010; 14:356–362.

11. Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18:293–313.

12. Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019; 4:e126908.

13. Kudo M. Immune checkpoint blockade in hepatocellular carcinoma. Liver Cancer. 2015; 4:201–207.

14. El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Yau TC, Yeo WN, et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol. 2015; 33 Suppl 15:LBA101.

15. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015; 16:257–265.

16. Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nat Immunol. 2018; 19:222–232.

17. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012; 12:860–875.

18. Lu J, Liu X, Liao YP, Salazar F, Sun B, Jiang W, et al. Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression. Nat Commun. 2017; 8:1811.

19. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015; 3:436–443.

20. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017; 389:2492–2502.

21. Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, et al. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer. Hepatology. 2019; 69:2048–2060.

22. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol. 2017; 66:545–551.

23. Kudo M. Immuno-oncology therapy for hepatocellular carcinoma: current status and ongoing trials. Liver Cancer. 2019; 8:221–238.

24. Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021; 18:525–543.

25. Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, et al. Immunotherapy for hepatocellular carcinoma: current status and future prospects. Front Immunol. 2021; 12:765101.

26. Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, et al. Safety of combined yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020; 31:25–34.

27. Prieto J, Melero I, Sangro B. Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2015; 12:681–700.

28. Greten TF, Wang XW, Korangy F. Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches. Gut. 2015; 64:842–848.

29. Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma. World J Gastroenterol. 2015; 21:10314–10326.

30. Centanni M, Moes DJAR, Trocóniz IF, Ciccolini J, van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019; 58:835–857.

31. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49:493–507.

32. Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019; 18:175–196.

33. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncol. 2016; 2:1346–1353.

34. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5:95.

35. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018; 4:1721–1728.

36. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, et al. Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol. 2015; 33:3193–3198.

37. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017; 35:785–792.

38. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017; 377:1345–1356.

39. Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016; 17:1558–1568.

40. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019; 381:2020–2031.

41. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373:1270–1271.

42. Nakajima EC, Lipson EJ, Brahmer JR. Challenge of rechallenge: when to resume immunotherapy following an immune-related adverse event. J Clin Oncol. 2019; 37:2714–2718.

43. Choi YH, Han HK. Nanomedicines: current status and future perspectives in aspect of drug delivery and pharmacokinetics. J Pharm Investig. 2018; 48:43–60.

44. Kim DH. Image-Guided Cancer Nanomedicine. J Imaging. 2018; 4:18.

45. Yu B, Zhang W, Kwak K, Choi H, Kim DH. Electric pulse responsive magnetic nanoclusters loaded with indoleamine 2,3-dioxygenase inhibitor for synergistic immuno-ablation cancer therapy. ACS Appl Mater Interfaces. 2020; 12:54415–54425.

46. Choi B, Choi H, Yu B, Kim DH. Synergistic local combination of radiation and anti-programmed death ligand 1 immunotherapy using radiation-responsive splintery metallic nanocarriers. ACS Nano. 2020; 14:13115–13126.

47. Yu B, Choi B, Li W, Kim DH. Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. Nat Commun. 2020; 11:3637.

48. Choi B, Jung H, Yu B, Choi H, Lee J, Kim DH. Sequential MR imageguided local immune checkpoint blockade cancer immunotherapy using ferumoxytol capped ultralarge pore mesoporous silica carriers after standard chemotherapy. Small. 2019; 15:e1904378.

49. Wang D, Wang T, Yu H, Feng B, Zhou L, Zhou F, et al. Engineering nanoparticles to locally activate T cells in the tumor microenvironment. Sci Immunol. 2019; 4:e. aau6584.

50. Bu J, Nair A, Iida M, Jeong WJ, Poellmann MJ, Mudd K, et al. An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy. Nano Lett. 2020; 20:4901–4909.

51. Jiang CT, Chen KG, Liu A, Huang H, Fan YN, Zhao DK, et al. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy. Nat Commun. 2021; 12:1359.

52. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016; 1:16014.

53. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33:941–951.

54. Bertrand N, Grenier P, Mahmoudi M, Lima EM, Appel EA, Dormont F, et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat Commun. 2017; 8:777.

55. Desnoyer A, Broutin S, Delahousse J, Maritaz C, Blondel L, Mir O, et al. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies. Eur J Cancer. 2020; 128:119–128.

56. Yong KW, Yuen D, Chen MZ, Porter CJH, Johnston APR. Pointing in the right direction: controlling the orientation of proteins on nanoparticles improves targeting efficiency. Nano Lett. 2019; 19:1827–1831.

57. Kwak K, Yu B, Mouli SK, Larson AC, Kim DH. Sodium cholate bile acid-stabilized ferumoxytol-doxorubicin-lipiodol emulsion for transcatheter arterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2020; 31:1697–1705. e3.

58. Park W, Cho S, Kang D, Han JH, Park JH, Lee B, et al. Tumor microenvironment targeting nano-bio emulsion for synergistic combinational X-Ray PDT with oncolytic bacteria therapy. Adv Healthc Mater. 2020; 9:e1901812.

59. Choi B, Kim DH. Multifunctional nanocarriers-mediated synergistic combination of immune checkpoint inhibitor cancer immunotherapy and interventional oncology therapy. Adv NanoBiomed Res. 2021; 1:100010.

60. Lien WM, Ackerman NB. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. Surgery. 1970; 68:334–340.

61. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004; 60:1552–1563.

62. Choi H, Choi B, Yu B, Li W, Matsumoto MM, Harris KR, et al. Ondemand degradable embolic microspheres for immediate restoration of blood flow during image-guided embolization procedures. Biomaterials. 2021; 265:120408.

63. Ji J, Park WR, Cho S, Yang Y, Li W, Harris K, et al. Iron-oxide nanocluster labeling of clostridium novyi-NT spores for MR imaging-monitored locoregional delivery to liver tumors in rat and rabbit models. J Vasc Interv Radiol. 2019; 30:1106–1115. e1.

64. Cho S, Min NG, Park W, Kim SH, Kim DH. Janus microcarriers for magnetic field-controlled combination chemotherapy of hepatocellular carcinoma. Adv Funct Mater. 2019; 29:1901384.

65. Matsumoto MM, Kim DH, Larson AC, Mouli SK. Interventional nanotheranostics: advancing nanotechnology applications with IR. J Vasc Interv Radiol. 2019; 30:1824–1829. e1.

66. Gournaris E, Park W, Cho S, Bentrem DJ, Larson AC, Kim DH. Nearinfrared fluorescent endoscopic image-guided photothermal ablation therapy of colorectal cancer using dual-modal gold nanorods targeting tumor-infiltrating innate immune cells in a transgenic TS4 CRE/APC loxΔ468 mouse model. ACS Appl Mater Interfaces. 2019; 11:21353–21359.

67. Park W, Cho S, Ji J, Lewandowski RJ, Larson AC, Kim DH. Development and validation of sorafenib-eluting microspheres to enhance therapeutic efficacy of transcatheter arterial chemoembolization in a rat model of hepatocellular carcinoma. Radiol Imaging Cancer. 2021; 3:e200006.

68. Park W, Kim SJ, Cheresh P, Yun J, Lee B, Kamp DW, et al. Magneto mitochondrial dysfunction mediated cancer cell death using intracellular magnetic nano-transducers. Biomater Sci. 2021; 9:5497–5507.

69. Lencioni R, Cioni D, Crocetti L, Bartolozzi C. Percutaneous ablation of hepatocellular carcinoma: state-of-the-art. Liver Transpl. 2004; 10(2 Suppl 1):S91–S97.

70. Adusumilli PS, Zauderer MG, Rusch VW, O'Cearbhaill RE, Zhu A, Ngai DA, et al. A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Cancer Res. 2019; 79(Suppl 13):CT036.

71. Ishikawa W, Kikuchi S, Ogawa T, Tabuchi M, Tazawa H, Kuroda S, et al. boosting replication and penetration of oncolytic adenovirus by paclitaxel eradicate peritoneal metastasis of gastric cancer. Mol Ther Oncolytics. 2020; 18:262–271.